Eloxx Pharmaceuticals, Inc. SEC Filings

Eloxx Pharmaceuticals director files initial ownership report

Eloxx Pharmaceuticals, Inc. director Nina S. Kjellson has filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing does not list any stock or option transactions and serves mainly to register her insider status with regulators.

Coastlands Capital LP, a ten percent owner of Eloxx Pharmaceuticals, Inc., reported an internal restructuring of its position. On May 27, 2026, it exchanged 1,250,000 shares of common stock for pre-funded warrants to purchase an equivalent number of common shares at an exercise price of $0.01 per share. Following the transaction, Coastlands held no common stock indirectly through Coastlands Capital LP and instead reported 30,612,243 pre-funded warrants. These pre-funded warrants are exercisable at any time, have no expiration date, and are subject to a 4.99% beneficial ownership limitation, which restricts exercises that would push holdings above that level.

Eloxx Pharmaceuticals — Amendment No. 1 to a Schedule 13G/A: Coastlands-related reporting persons state they beneficially own 266,539 shares of Common Stock, representing 4.99% based on 5,074,935 shares outstanding as of May 27, 2026. The filing describes these shares as issuable upon exercise of pre-funded warrants and notes this Amendment constitutes an exit filing because the reporting persons no longer beneficially own more than 5% of any class of the issuer's securities.

Eloxx Pharmaceuticals director Steven D. Rubin reported routine equity compensation activity. On January 24, 2026, he exercised 1,875 restricted stock units (RSUs), receiving an equal number of common shares at $0.00 per share, lifting his direct common stock holdings to 14,625 shares.

Following this RSU conversion, Rubin still held 1,875 RSUs. Earlier, on September 19, 2025, he received a grant of 179,854 stock options for common stock at a $0.15 exercise price, vesting 1/36 on October 31, 2025, then in equal monthly installments over 35 months until September 2035.

Eloxx Pharmaceuticals’ President and CEO Sumit Aggarwal reported a series of compensation-related equity moves. On February 28, 2026, he exercised options to acquire 260,946 shares of common stock at $0.15 per share, bringing his directly held common stock to 1,672,756 shares.

Earlier, on January 24, 2026, 15,000 restricted stock units converted into an equal number of common shares. On September 19, 2025, he received an award of 1,000,000 common shares and 3,597,090 stock options with a $0.15 exercise price expiring in 2035. On August 14, 2025, he exercised options to acquire 196,880 shares at an exercise price of $0.0001 per share.

Footnotes state that several older options granted in 2021–2023 were cancelled and replaced with new options at lower exercise prices, and that the board accelerated vesting or waived performance conditions in connection with certain exercises and grants.

Eloxx Pharmaceuticals director Alan Edmund Walts reported equity compensation activity, not open‑market trading. On January 24, 2026, he exercised 1,875 restricted stock units, receiving an equal number of common shares at a stated price of $0.00 per share, bringing his directly held common stock to 15,567 shares.

A prior grant on September 19, 2025 awarded him a stock option for 395,680 shares of common stock at an exercise price of $0.15 per share, expiring on September 19, 2035. The option vests over 36 months, and the RSUs vested 50% after one year with the balance in two annual installments.

Eloxx Pharmaceuticals, Inc. informs stockholders that holders of a majority of its common stock approved corporate actions by written consent on April 28, 2026. The Board and Majority Stockholders approved (1) a First Amendment increasing the 2018 Equity Incentive Plan share reserve to 20,000,000 shares, (2) an amended and restated 2018 Equity Incentive Plan with an ISO limit of 80,000,000 shares and an evergreen extension to January 1, 2036, and (3) a reverse stock split to be effected at a Board-determined ratio between 1-for-2 and 1-for-20 to be implemented, if any, on or prior to the one-year anniversary of the record date. The Information Statement states there were 7,573,935 shares of Common Stock outstanding as of the record date and notes the Company intends to file a registration statement covering shares under the Restated 2018 Plan.

Eloxx Pharmaceuticals, Inc. is seeking to raise capital through a public offering of common stock and pre-funded warrants, with the closing contingent on securing a listing of its common stock on the Nasdaq Capital Market under the symbol “ELOX”. The company is currently quoted on the OTC Expert Market and was previously delisted from Nasdaq after failing to meet market value requirements and becoming delinquent in SEC filings.

Eloxx is a clinical-stage biopharmaceutical company focused on exaluren, a ribosome-modulating small molecule being developed for Alport syndrome with nonsense mutations and autosomal dominant polycystic kidney disease, and on ZKN-013, which is licensed to Almirall for rare skin diseases. The company reported a net loss of $6.0 million in 2025 and $3.8 million for the three months ended March 31, 2026, had $6.4 million in cash and cash equivalents and an accumulated deficit of $304.3 million, and its auditors expressed substantial doubt about its ability to continue as a going concern.

Eloxx Pharmaceuticals reported a larger net loss of $3.8M for the quarter ended March 31, 2026, compared with $1.7M a year earlier, as it increased spending on drug development and corporate overhead.

Research and development expenses rose to $1.7M and general and administrative costs climbed to $2.1M. Eloxx ended the quarter with $6.4M in cash, after raising about $7.0M through pre-funded warrant financings and eliminating its remaining debt. Management and the auditors state that recurring losses and limited cash create substantial doubt about the company’s ability to continue as a going concern, absent additional capital.